📣 VC round data is live. Check it out!
- Public Comps
- Monte Rosa Therapeutics
Monte Rosa Therapeutics Valuation Multiples
Discover revenue and EBITDA valuation multiples for Monte Rosa Therapeutics and similar public comparables like Palvella Therapeutics, Immunocore Holdings, AnaptysBio, Alembic Pharmaceuticals and more.
Monte Rosa Therapeutics Overview
About Monte Rosa Therapeutics
Monte Rosa Therapeutics Inc is a biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. With a diverse library of over 50,000 MGD molecules, their product candidate, MRT-2359, targets the translation termination factor protein GSPT1 for potential use in MYC-driven tumors. The company's focus lies in advancing its pipeline of MGDs, aiming to provide novel therapeutic modalities for various diseases.
Founded
2019
HQ

Employees
134
Website
Financials (LTM)
EV
$872M
Valuation Multiples
Start free trialMonte Rosa Therapeutics Financials
Monte Rosa Therapeutics reported last 12-month revenue of $90M and negative EBITDA of ($46M).
In the same LTM period, Monte Rosa Therapeutics generated $90M in gross profit, ($46M) in EBITDA losses, and had net loss of ($93M).
Revenue (LTM)
Monte Rosa Therapeutics P&L
In the most recent fiscal year, Monte Rosa Therapeutics reported revenue of $124M and EBITDA of ($46M).
Monte Rosa Therapeutics is unprofitable as of last fiscal year, with EBITDA margin of (37%) and net margin of (31%).
Financial data powered by Morningstar, Inc.
Monte Rosa Therapeutics Stock Performance
Monte Rosa Therapeutics has current market cap of $1B, and enterprise value of $872M.
Market Cap Evolution
Monte Rosa Therapeutics' stock price is $17.74.
Monte Rosa Therapeutics share price decreased by 10.0% in the last 30 days, and increased by 294.7% in the last year.
Monte Rosa Therapeutics has an EPS (earnings per share) of $-0.46.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $872M | $1B | -9.9% | -10.0% | 7.8% | 294.7% | $-0.46 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialMonte Rosa Therapeutics Valuation Multiples
Monte Rosa Therapeutics trades at 9.7x EV/Revenue multiple, and (19.0x) EV/EBITDA.
EV / Revenue (LTM)
Monte Rosa Therapeutics Financial Valuation Multiples
As of June 3, 2026, Monte Rosa Therapeutics has market cap of $1B and EV of $872M.
Monte Rosa Therapeutics has a P/E ratio of (16.1x).
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Monte Rosa Therapeutics Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


Monte Rosa Therapeutics Margins & Growth Rates
Monte Rosa Therapeutics decreased revenue by 64% and EBITDA by 25% in the last fiscal year.
In the most recent fiscal year, Monte Rosa Therapeutics reported EBITDA margin of (37%) and net margin of (31%).
Monte Rosa Therapeutics Margins
Monte Rosa Therapeutics Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
Monte Rosa Therapeutics Operational KPIs
Monte Rosa Therapeutics' revenue per employee in the last FY averaged $0.9M, while opex per employee averaged $1.3M for the same period.
Monte Rosa Therapeutics' Rule of 40 is (141%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Monte Rosa Therapeutics' Rule of X is (237%) (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Data powered by FactSet, Inc. and Morningstar, Inc.
Monte Rosa Therapeutics Competitors
Monte Rosa Therapeutics competitors include Palvella Therapeutics, Immunocore Holdings, AnaptysBio, Alembic Pharmaceuticals, Amylyx Pharmaceuticals, Vir Biotechnology, Biohaven, Ab&B Bio-Tech, InventisBio and MBX Biosciences.
Most Monte Rosa Therapeutics public comparables operate across Biopharmaceuticals, BioTech and DeepTech.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| - | - | (34.5x) | (25.5x) | |||
| 2.7x | 2.6x | (298.4x) | (47.1x) | |||
| 5.2x | 6.5x | 17.6x | 18.8x | |||
| 2.4x | 2.1x | 14.5x | 13.5x | |||
| - | - | (7.9x) | (7.5x) | |||
| 15.9x | 10.1x | (2.4x) | (2.8x) | |||
| - | - | (2.0x) | (2.4x) | |||
| 41.5x | - | (59.2x) | - | |||
This data is available for Pro users. Sign up to see all Monte Rosa Therapeutics competitors and their valuation data. Start Free Trial | ||||||
Monte Rosa Therapeutics VC Funding History
Before going public, Monte Rosa Therapeutics raised $224M in total equity funding, across 3 rounds.
Monte Rosa Therapeutics Funding Rounds
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Monte Rosa Therapeutics
| When was Monte Rosa Therapeutics founded? | Monte Rosa Therapeutics was founded in 2019. |
| Where is Monte Rosa Therapeutics headquartered? | Monte Rosa Therapeutics is headquartered in United States. |
| How many employees does Monte Rosa Therapeutics have? | As of today, Monte Rosa Therapeutics has over 134 employees. |
| Who is the CEO of Monte Rosa Therapeutics? | Monte Rosa Therapeutics' CEO is Markus Warmuth. |
| Is Monte Rosa Therapeutics publicly listed? | Yes, Monte Rosa Therapeutics is a public company listed on Nasdaq. |
| What is the stock symbol of Monte Rosa Therapeutics? | Monte Rosa Therapeutics trades under GLUE ticker. |
| When did Monte Rosa Therapeutics go public? | Monte Rosa Therapeutics went public in 2021. |
| Who are competitors of Monte Rosa Therapeutics? | Monte Rosa Therapeutics main competitors include Palvella Therapeutics, Immunocore Holdings, AnaptysBio, Alembic Pharmaceuticals, Amylyx Pharmaceuticals, Vir Biotechnology, Biohaven, Ab&B Bio-Tech, InventisBio, MBX Biosciences. |
| What is the current market cap of Monte Rosa Therapeutics? | Monte Rosa Therapeutics' current market cap is $1B. |
| What is the current revenue of Monte Rosa Therapeutics? | Monte Rosa Therapeutics' last 12 months revenue is $90M. |
| What is the current revenue growth of Monte Rosa Therapeutics? | Monte Rosa Therapeutics revenue growth (NTM/LTM) is (44%). |
| What is the current EV/Revenue multiple of Monte Rosa Therapeutics? | Current revenue multiple of Monte Rosa Therapeutics is 9.7x. |
| Is Monte Rosa Therapeutics profitable? | No, Monte Rosa Therapeutics is not profitable. |
| What is the current EBITDA of Monte Rosa Therapeutics? | Monte Rosa Therapeutics has negative EBITDA and is not profitable. |
| What is Monte Rosa Therapeutics' EBITDA margin? | Monte Rosa Therapeutics' last 12 months EBITDA margin is (51%). |
| What is the current EV/EBITDA multiple of Monte Rosa Therapeutics? | Current EBITDA multiple of Monte Rosa Therapeutics is (19.0x). |
| What is the current FCF of Monte Rosa Therapeutics? | Monte Rosa Therapeutics' last 12 months FCF is ($22M). |
| What is Monte Rosa Therapeutics' FCF margin? | Monte Rosa Therapeutics' last 12 months FCF margin is (25%). |
| What is the current EV/FCF multiple of Monte Rosa Therapeutics? | Current FCF multiple of Monte Rosa Therapeutics is (38.8x). |
| How many companies Monte Rosa Therapeutics has acquired to date? | Monte Rosa Therapeutics hasn't acquired any companies yet (or none have been disclosed publicly). |
| In how many companies Monte Rosa Therapeutics has invested to date? | Monte Rosa Therapeutics hasn't invested in any companies yet (or none have been disclosed publicly). |
See public comps similar to Monte Rosa Therapeutics
Lists including Monte Rosa Therapeutics
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.